Related references
Note: Only part of the references are listed.2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
Maansi Joshi et al.
BLOOD CANCER JOURNAL (2021)
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Matthew E. Tenold et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl et al.
BLOOD ADVANCES (2021)
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
Cindy M. Pabon et al.
BLOOD CANCER JOURNAL (2021)
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
Hee-Je Kim et al.
BLOOD CANCER JOURNAL (2021)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
Rabia Shahswar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
Kristin Koenig et al.
CURRENT OPINION IN HEMATOLOGY (2020)
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia
Michael Byrne et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Heuser et al.
ANNALS OF ONCOLOGY (2020)
Treatment of Relapsed Acute Myeloid Leukemia
Felicitas Thol et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression
Silvia Park et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms
Joonhong Park et al.
MOLECULAR DIAGNOSIS & THERAPY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
Brian A. Jonas et al.
LEUKEMIA (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia
Rafiye Ciftciler et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Interpretation of clinical endpoints in trials of acute myeloid leukemia
Bruno C. Medeiros
LEUKEMIA RESEARCH (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia A retrospective cohort study
Jun Xu et al.
MEDICINE (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)
Chantal Fridle et al.
LEUKEMIA & LYMPHOMA (2017)
Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types
Jae-Ho Yoon et al.
ONCOTARGET (2017)
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
J. M. Middeke et al.
LEUKEMIA (2016)
Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol
Rebecca Llewellyn-Bennett et al.
SYSTEMATIC REVIEWS (2016)
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
Khoan Vu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length
Y. Kim et al.
BLOOD CANCER JOURNAL (2015)
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
R. B. Walter et al.
LEUKEMIA (2015)
Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia
F. Stoelzel et al.
LEUKEMIA (2013)
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia
Steven M. Trifilio et al.
LEUKEMIA RESEARCH (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia
Ki-Seong Eom et al.
MEDICAL ONCOLOGY (2011)
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
Mark R. Litzow et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clofarabine Combinations as Acute Myeloid Leukemia Salvage Therapy
Stefan Faderl et al.
CANCER (2008)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia:: prognostic significance and relation to cellular drug resistance
CM Zwaan et al.
BLOOD (2003)
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience
D Pastore et al.
ANNALS OF HEMATOLOGY (2003)
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
G Jackson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia
T Robak et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
